Association of CD49d and CD44 in CLL Patients and Their Role in Prognosis

December 15, 2017 updated by: ALShymaa faheem solyman ali, Assiut University
The interactions of chronic lymphocytic leukemia cells with the microenvironment in secondary lymphoid tissues and the bone marrow are known to promote CLL cell survival and proliferation

Study Overview

Status

Unknown

Conditions

Detailed Description

Chronic lymphocytic leukemia (CLL) is the most common type of chronic leukemia, accounting for approximately 40% of all leukemia's and mainly affecting older individuals. As it has a highly variable clinical course, identification of molecular and biological prognostic markers has provided new insights into the risk stratification of patients with CLL .

The interactions of chronic lymphocytic leukemia cells with the microenvironment in secondary lymphoid tissues and the bone marrow are known to promote CLL cell survival and proliferation . CD49d (one of biomarkers) is one of independent prognostic risk parameter in CLL with important roles in shaping these interactions.

CD49d also is one of independent prognostic risk parameters in CLL that predict adverse outcome and linked to processes involved in interaction with the vascular endothelium and/or migration into the extravascular compartments .

The cell-surface glycoprotein CD44 is involved in cell motility, cellular trafficking, and stem cell differentiation . It contributes to the phenotypic hallmarks of many cancers, such as invasiveness, self-renewal, and sustained survival. CD44 transmits both growth and apoptotic signals, a functional duality that is also observed in hematologic malignancies.

CD44 expression in CLL is mediated by the tumor microenvironment. As a coreceptor, CD44 promotes leukemogenesis by regulating stimuli of MCL1 expression. Moreover, CD44 can be addressed therapeutically in CLL by specific antibodies.

Study Type

Observational

Enrollment (Anticipated)

2

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

30 patients All patients are newly diagnosed as CLL patients with associated malignancies

  • Clinical history and clinical examination by the physician.
  • Complete blood picture: on peripheral blood sample.
  • BM aspiration: allowing diagnosis of the type of leukemia.
  • Immunophenotyping by flowcytometer: will be done on peripheral blood or bone marrow aspirate specimens for establishing diagnosis of CLL by detecting its markers ( CD5,CD19,CD23) and for detecting membrane expression of CD49d and CD 44

Description

Inclusion Criteria:

  • All patients are newly diagnosed as CLL

Exclusion Criteria:

  • : patients with associated malignancies

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To what extent the identification of molecular and biological prognostic markers has provided new insights into the risk stratification of patients with CLL .
Time Frame: 1 YEAR
detecting membrane expression of CD49d and CD 44 and thier role in prognosis of CLL patients.
1 YEAR

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assiut University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 14, 2016

Primary Completion (Anticipated)

September 14, 2018

Study Completion (Anticipated)

December 14, 2018

Study Registration Dates

First Submitted

December 8, 2017

First Submitted That Met QC Criteria

December 15, 2017

First Posted (Actual)

December 21, 2017

Study Record Updates

Last Update Posted (Actual)

December 21, 2017

Last Update Submitted That Met QC Criteria

December 15, 2017

Last Verified

December 1, 2017

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 1700258

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cellular Diagnosis, Chronic Lymphocytic Leukemia

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Benin

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe